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Oligomeric forms of amyloid- (A) are thought to play a causal role in Alzheimer’s disease (AD), and the p75 neurotrophin receptor
(p75 NTR) has been implicated in A-induced neurodegeneration. To further define the functions of p75 NTR in AD, we examined the
interaction of oligomeric A(1-42) with p75 NTR, and the effects of that interaction on neurite integrity in neuron cultures and in a chronic
AD mouse model. Atomic force microscopy was used to ascertain the aggregated state of A, and fluorescence resonance energy transfer
analysis revealed that A oligomers interact with the extracellular domain of p75 NTR. In vitro studies of A-induced death in neuron
culturesisolatedfromwild-typeandp75NTR/mice, inwhichthep75NTR extracellulardomainisdeleted,showedreducedsensitivityofmutant
cells to A-induced cell death. Interestingly, A-induced neuritic dystrophy and activation of c-Jun, a known mediator of A-induced deleteri-
ous signaling, were completely prevented in p75NTR/ neuron cultures. Thy1-hAPPLond/Swe  p75NTR/ mice exhibited significantly dimin-
ished hippocampal neuritic dystrophy and complete reversal of basal forebrain cholinergic neurite degeneration relative to those expressing
wild-type p75NTR. A levels were not affected, suggesting that removal of p75NTR extracellular domain reduced the ability of excess A to
promote neuritic degeneration. These findings indicate that although p75NTR likely does not mediate all A effects, it does play a significant role
in enabling A-induced neurodegeneration in vitro and in vivo, establishing p75NTR as an important therapeutic target for AD.
Introduction
The p75 neurotrophin receptor (p75 NTR) is a potential therapeu-
tic target for Alzheimer’s disease (AD) (Longo and Massa, 2004b;
Coulson, 2006; Longo et al., 2007). p75 NTR regulates neuron sur-
vival, function, and structure by acting in concert with a collec-
tion of ligands and coreceptors (Dechant and Barde, 2002; Longo
and Massa, 2008). Nerve growth factor (NGF) signaling through
p75 NTR may induce death or survival depending on the cellular
context, whereas the pro form of NGF signals through p75 NTR
and sortilin to induce death (Barker, 2004; Nykjaer et al., 2004).
p75 NTR also regulates neurite outgrowth through its interactions
with the Nogo and LINGO coreceptors (Wang et al., 2002; Mi et
al., 2004). p75 NTR is expressed by populations that are particu-
larly vulnerable in AD, including basal forebrain cholinergic, hip-
pocampal, cortical, and entorhinal neurons (Longo and Massa,
2004b); and its expression is further increased in AD (Mufson
and Kordower, 1992; Hu et al., 2002). Amyloid- (A) (1-40)
aggregates of undetermined structure have been reported to be
death-inducing ligands of p75 NTR (Yaar et al., 1997, 2002), al-
though A is also known to bind multiple other targets (Verdier
and Penke, 2004). p75 NTR mediates A-induced death in hip-
pocampal neurons (Sotthibundhu et al., 2008), PC12 cells
(Rabizadeh et al., 1994), NIH 3T3 cells (Yaar et al., 1997), and
human neuroblastoma cells (Perini et al., 2002), an effect requiring
the receptor extracellular domain (Perini et al., 2002). A toxicity
mediated by p75 NTR occurs via c-Jun kinase (JNK) and the tran-
scription factor, c-Jun (Morishima et al., 2001; Hashimoto et al.,
2004; Yaar et al., 2007). In addition, low level A exposure may
promote aberrant neurite outgrowth via p75 NTR (Susen and
Blochl, 2005). Finally, recent studies have found that A causes
substantially less neuronal death when injected into the hip-
pocampus of p75 NTR/ mutant mice (in which exon III, which
constitutes a large part of the extracellular domain of p75 NTR, is
deleted), than in wild-type (p75 NTR/) mice (Sotthibundhu et
al., 2008).
To further establish whether targeting of p75 NTR might have a
therapeutic role in AD, we addressed three questions regarding
A and p75 NTR function. A first series of studies applied fluores-
cence resonance energy transfer (FRET)-based technology to
investigate oligomeric A interactions with the extracellular do-
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main of p75 NTR. A second series of experiments used neuronal
cultures derived from p75 NTR/ mutant mice, to examine
p75 NTR contributions to oligomeric A-induced cell death, neu-
rite degeneration, and c-Jun signaling. Finally, we determined the
effects of p75 NTR on chronic A-induced neuronal degeneration
in vivo by crossing p75 NTR/ mice with Thy1-hAPP Lond/Swe
mice, a well characterized mouse model of AD (Rockenstein et
al., 2001). The results support the ideas that oligomeric A inter-
acts with the extracellular domain of p75 NTR and that p75 NTR is
required for A-induced deleterious signaling and neurodegen-
eration, including neuritic degeneration, in vitro and in vivo.
These findings point to p75 NTR as a significant therapeutic target
for slowing or preventing fundamental pathologic mechanisms
underlying AD.
Materials and Methods
Materials. Anti-phospho-c-Jun (p-c-Jun) polyclonal antibody was
purchased from Cell Signaling Technology; microtubule-associated
protein-2 (MAP-2) monoclonal antibody was purchased from Sigma.
The p75 NTR-blocking rabbit antibody 9651, directed against residues
43-161 of the extracellular domain cysteine repeat regions II, III, and IV,
was obtained from Dr. Moses Chao (Skirball Institute, New York Uni-
versity, New York, NY) (Huber and Chao, 1995). Recombinant NGFR/
TNFRSF16/Fc chimera protein, encoding residues 1-250 of the extracel-
lular domain of human p75 NTR fused to an Fc fragment, was expressed in
Sf 21 cells using a baculovirus vector (obtained from R&D Systems).
Cy3B-NHS ester was purchased from GE Healthcare Bio-Sciences.
5-FAM-X, SE [6-(fluorescein-5-carboxamido)hexanoic acid, succinimi-
dyl ester] was obtained from AnaSpec. Fluorescein-labeled A(1-42)
peptide was purchased from AnaSpec. 8E5 anti-APP (amyloid precursor
protein) antibody was obtained from Elan Pharmaceuticals. Goat anti-
ChAT AB144P antibody and biotinylated rabbit anti-goat antibodies
were obtained from Millipore Bioscience Research Reagents. Control
rabbit IgG was purchased from Invitrogen. Secondary fluorescent anti-
bodies were obtained from Jackson ImmunoResearch Laboratories.
Thioflavin-S and cresyl violet stains were procured from Sigma.
A preparations. For work in neuronal cultures, A(1-42) peptide was
obtained from rPeptide and A oligomers were prepared. In early exper-
iments, A peptide was resuspended in 0.2% NH4OH (Bozyczko-Coyne
et al., 2001) at a concentration of 350 M and stored at 70°C. The stock
solution was incubated at 37°C for 5–7 d before application in cell cul-
tures. In the majority of experiments, 1.0 mg of A peptide was dissolved
in 250 l of hexafluoroisopropanol (HFIP), aliquoted in microcentrifuge
tubes, and HFIP was removed under vacuum in a SpeedVac (Stine et al.,
2003). Resulting peptide films were stored desiccated at 20°C. Before
use, the peptide was resuspended to 2.5 mM in dry DMSO (Sigma),
brought to 80 M in PBS, and incubated at 4°C for 24 h. We have previ-
ously verified by atomic force microscopy (AFM) that A prepared ac-
cording to each of these protocols reliably forms oligomers that have
indistinguishable toxic potency in neuron culture (Yang et al., 2008). For
FRET analysis, oligomers of fluorescein-labeled A(1-42) peptide were
prepared using the HFIP-based protocol. To verify that fluorescein-
labeled A prepared with the HFIP-based protocol forms oligomers,
nonlabeled AFM topography images were acquired in the light tapping
mode using a MultiMode AFM (Veeco) controlled by a Nanoscope IIIA
controller (Veeco). Resonant frequencies of the uncoated silicon tips
(MikroMasch) were 150 kHz with tip radii 10 nm. Samples were
made by dispersing solutions onto Pirahna cleaned silicon wafers with
molecular smoothness 1 Å rms roughness as determined by AFM.
FRET spectroscopy. p75 NTR extracellular domain was labeled with
Cy3B-NHS ester using standard protein coupling protocols recom-
mended by the manufacturers. Briefly, 50 g of Cy3B-NHS ester in 20 l
of dimethylformamide (DMF) was reacted with 100 g of p75 NTR extra-
cellular domain dissolved in 200 l of 50 mM borate buffer, pH 8.3. This
solution was incubated at room temperature for 2 h. Nonreactive dye was
separated using prepacked, disposable PD-10 columns containing Seph-
adex G-25 (GE Healthcare Bio-Sciences). Cy3B-p75 NTR was eluted with
20 mM sodium phosphate buffer, pH 7.2, stored in the same buffer at 4°C,
and used within 2 d. Biotinylated IgG was labeled with Cy3B-NHS using
the same protocol. Streptavidin-FITC was obtained from R&D Systems.
To link 5-FAM-X, SE (fluorescein) with NGF or p75 NTR, 100 g of 2.5S
NGF or recombinant p75 NTR was dissolved in 200 l of bicarbonate
buffer of pH 8.3 and treated with 20 l containing 50 g of fluorescein in
DMF. This solution was incubated at room temperature for 2 h. Nonre-
active dye was separated using Sephadex G-25 PD-10 columns as above.
Fluorescein-NGF was eluted with 20 mM sodium phosphate buffer, pH
7.2, and stored in the same buffer at 4°C and used within 2 d. Because
fluorescein is known for its self-quenching properties that would lead to
lowering of fluorescence intensity with increasing aggregation (Lakowicz
et al., 2003), we diluted fluorescein-A with unlabeled A in a 1:3 ratio.
Aliquots of 10 mM PBS solution containing 0.7% BSA and various com-
binations of fluorescein- or Cy3B-labeled A, p75 NTR, NGF, biotinyl-
ated IgG, Streptavidin, or BSA were allowed to equilibrate for 2 h at
room temperature and then subjected to FRET analysis using ultra-
microfluorescence cuvettes with a sample capacity of 45 l. Heat-denatured
p75NTR-Cy3B and BSA-Cy3B were used as negative controls. The excitation
wavelength was set as 490 nm, and intensity of fluorescent emissions was
recorded between 500 and 750 nm. Fluorescence measurements were per-
formed using a Fluorolog-Spectro fluorometer equipped with a xenon lamp.
Both the excitation and emission slits were set at 1 nm.
Primary neuronal cultures. All animal procedures were approved by the
Stanford Committee on Laboratory Animal Care and were conducted in
accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals. Hippocampal and basal forebrain cultures
were prepared from embryonic day (E) 15–17 C57BL/6 mice that ex-
pressed normal p75 NTR (p75 NTR/) or from mice lacking exon III
(extracellular domain) of p75 NTR (p75 NTR/) (Lee et al., 1992). In
studies that did not require p75 NTR/ neurons, hippocampal neurons
were cultured from E16 CF-1 mouse fetuses. Tissue culture wells with or
without coverslips were coated with 10 g/ml poly-L-lysine in PBS. Cells
were incubated in DMEM/F12 containing 10% fetal bovine serum and 1
mM Glutamax supplement for the first 24 h, and subsequently main-
tained in serum-free Neurobasal medium with 1 B27 and Glutamax
supplement (Invitrogen) and antibiotics (penicillin/streptomycin and
Fungizone, Invitrogen). For neuronal viability assays, neurons were
seeded in 12-well plates at a density of 100,000 cells per well and allowed
to mature 6 –7 d. For neuritic dystrophy assays, 200,000–300,000 neurons
per well were seeded into six-well plates containing 25 mm coverslips and
matured for 21–22 d. Culture medium was changed every 48–72 h. Under
these culture conditions, p75NTR/ hippocampal and basal forebrain cul-
tures contain 95% p75NTR-immunopositive neurons (supplemental Fig.
S1, available at www.jneurosci.org as supplemental material).
Quantitation of neuronal survival. Survival assays were performed us-
ing cultures at 6 –7 days in vitro (DIV), in which A was added to
p75 NTR/ or p75 NTR/ neurons or, in some cases, to CF-1 wild-type
neurons in the presence or absence of 9651 anti-p75 NTR antibody or IgG
antibody control, each added at a 1:500 dilution. After 72 h incubation,
neurons were stained with Syto 13 (Invitrogen) or terminal deoxynu-
cleotidyl transferase-mediated biotinylated UTP nick end labeling
(TUNEL)/4,6-diamidino-2-phenylindole dihydrochloride (DAPI), us-
ing the fluorescein-12-dUTP, DeadEnd Fluorometric TUNEL System
(Promega), and Vectashield  DAPI (Vector Laboratories). Stained neu-
rons were visualized under a fluorescence microscope (Leica DM IRE2)
using 520 nm (TUNEL, Syto 13) or 460 nm (DAPI, Hoechst) filters.
Survival of neurons was determined based on morphological criteria as
determined by phase-contrast microscopy and Syto13 (aids in cellular
visualization) (Eichler et al., 1992; Yang et al., 2008). Dead or degenerat-
ing neurons were defined as those with vacuolated cytoplasm, shrunken
cell bodies, and/or beaded or retracted neurites. Data are expressed as
percentage of the total number of observed neurons that were scored as
surviving. Neuron death was quantified with the TUNEL/DAPI system
by dividing the number of nuclei exhibiting TUNEL staining by the total
number of nuclei as identified by DAPI (Jana and Pahan, 2004).
Quantitation of neuritic dystrophy in hippocampal cultures. Hippocam-
pal neuron cultures (21 DIV) were treated with fresh culture medium
containing 5 M A for 48 h, then fixed in fresh 4% paraformaldehyde.
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Neurites were visualized by immunostaining with MAP-2 antibody. Dys-
trophic neurites are defined as those showing increased tortuosity (mul-
tiple abrupt turns) (Ferreira et al., 1997) and/or diminished volume. As
described previously (Yang et al., 2008), we quantitated the degree of
neurite tortuosity, using a modification of an established method for
assessment of neurite curvature (Knowles et al., 1999). Neurite courses
from randomly selected fields were traced by a blinded observer into a
series of n connected line segments using NIH Image software. The angle
of each segment relative to a line connecting the endpoints of the neurite
tracing (a) was calculated, each angle was subtracted from the previous
angle in the chain, and the results were averaged to give the “mean dif-
ferential curvature” score (MDC  	(ai  1  ai)/n). Thus, the MDC
indicates the extent to which tortuosity is present, with an increasing
score reflecting increased curvature. Neurite volumes were calculated
based on manual tracing with Neurolucida (Microbrightfield) and were
normalized to neuron length to control for neurite segments that passed
out of selected fields.
c-Jun signaling assay. p75 NTR/ or p75 NTR/ neurons (6 –7 DIV)
were treated with 5 M A for 10 –12 h, then fixed in fresh 4% parafor-
maldehyde and stained with p-c-Jun antibody and DAPI. Stained nuclei
were visualized using a Leica DM IRE2 light/fluorescence microscope.
The percentage of p-c-Jun expressing nuclei was quantitated in randomly
selected fields (Smith and Deshmukh, 2007; Yang et al., 2008).
Generation of p75NTR/, APP transgenic mice. All procedures were
conducted at the Palo Alto Veteran’s Administration Hospital with ap-
proval of the Committee on Animal Research. Studies used the well
characterized Thy1-hAPP Lond/Swe mouse model of Alzheimer’s disease,
which expresses human APP751 containing the London (V717I) and
Swedish (K670M/N671L) mutations under control of the Thy-1 pro-
moter, which is expressed postnatally (Rockenstein et al., 2001). Mice
were maintained on a C57BL/6 background. The presence or absence of
the mutant APP transgene is referred to as APP Lond/Swe and APP wt,
respectively. For the F1 cross, p75 NTR/, APP wt mice (Lee et al., 1992)
on a C57BL/6 background were crossed to APP Lond/Swe mice to obtain
the F2 generation of p75 NTR/, APP Lond/Swe or p75 NTR/, APP wt
mice. F2 mice were then intercrossed to generate multiple cohorts of
mice containing each of the six possible genotypes, including
p75 NTR/, APP Lond/Swe mice. Mice were aged to 5.5–7.5 months. In
Thy1-hAPP Lond/Swe mice, plaque deposition is known to occur by 3– 4
months of age in frontal cortex and by 5– 6 months in hippocampus
(Rockenstein et al., 2001). After a lethal dose of 2.8% chloral hydrate, mice
were perfused with saline (0.9% NaCl containing 2000 U/ml heparin).
Brains were fixed in fresh 4% paraformaldehyde for 24 h and cryoprotected
in 30% sucrose/PBS solution. Frozen coronal sections (50 m) were taken
through the entire brain using a Microm HM450 sliding microtome.
Immunohistochemistry. For hippocampal dystrophic neurite analysis,
sections were taken from the anterior hippocampus through bregma
2.7 mm at an intersection interval of 400 m (i.e., every eighth sec-
tion). The 8E5 anti-APP antibody (4.3 mg/ml) was biotinylated using the
ProtOn Kit from Vector Laboratories (PLK-1202), and after biotinyla-
tion, staining of dystrophic neurites was optimized at an antibody dilu-
tion of 1:1000. 8E5 is directed against residues 444-592 of the 770 form of
human APP (Games et al., 1995). A(1-42) comprises amino acids 672-
713 of human APP770; this antibody is not known to label A and,
therefore, does not label amyloid deposits such as plaques. However, it
does serve as a useful marker of dystrophic neurites, which accumulate in
the vicinity of amyloid plaques (Cras et al., 1991; Games et al., 1995;
Schenk et al., 1999).
8E5 antibody also labels cell bodies such as those in the dentate gyrus
and CA layers. Because our goal was to image neurite processes under-
going amyloid-induced degeneration, and not cell bodies, we focused on
the central area of the hippocampus comprising the stratum lacunosum-
moleculare, molecular layer of the dentate gyrus, and stratum radiatum,
a region which would be expected to contain both projection fibers of
hippocampal pyramidal neurons and granule cells, as well as septal cho-
linergic and entorhinal cortical efferent fibers.
Cholinergic cell bodies and neurites were labeled with anti-ChAT an-
tibody (Yeo et al., 1997) at a dilution of 1:400 and, in stereological and
Neurolucida studies, were counterstained with cresyl violet to visualize
tissue architecture. Immunostains were developed using diaminobenza-
dine (Sigma) and the Vectastain ABC detection kit (Vector Laborato-
ries). Amyloid plaques were labeled with 1% thioflavin-S stain.
Morphologic analyses of plaques and dystrophic neurites. Dystrophic
neurites and plaques were visualized using a Leica DM IRE2 light/fluo-
rescence microscope. Percentage area occupied by dystrophic neurites in
the central area of the hippocampus comprising the stratum lacunosum-
moleculare, molecular layer of the dentate gyrus, and stratum radiatum
was determined using ImageProPlus thresholding software (Media Cy-
bernetics) (Schenk et al., 1999; Noda-Saita et al., 2004). Percentage area
occupied by thioflavin-S-identified plaques in the hippocampus and cor-
tex tissue was determined with an analogous method (Khan et al., 2007).
Three to five sections were analyzed per mouse. One to three 10 fields
covering the entire hippocampal area of each section were analyzed to
achieve exhaustive sampling. For analysis of cortical plaque load, four
10 fields from cortex in the same sections that were used for hippocam-
pal analysis were selected by a blinded observer and analyzed to achieve
near exhaustive sampling (80 –90% total cortical area per section).
ELISA detection of amyloid-. Hippocampal or cortical tissue was son-
icated in radioimmunoprecipitation assay buffer (50 mM 1% Tris-HCl,
150 mM NaCl, 200 mM sodium orthovanadate, 1% NP40 detergent, 10%
sodium deoxycholate, 10% SDS, 2 protease inhibitor mixture) (Roche
Mini Tablet) and centrifuged in a Beckman TL100 ultracentrifuge at
45,000 rpm, 4°C for 30 min. The supernatant, containing soluble pro-
teins and A peptide, was retained. A(x-42) was captured using anti-
body 21F12 [5 g/ml, A(37-42); Elan Pharmaceuticals]-coated plates,
followed by detection with biotinylated 3D6 [2 g/ml, A(1-5); Elan
Pharmaceuticals]. Samples were incubated with the secondary antibody,
and then with avidin-HRP (1:4000 dilution; Vector Laboratories). Plates
were developed using tetramethylbenzidine (TMB) as substrate (one-
step Turbo TMB ELISA; Pierce Biotechnology), and optical density was
read at 450 nm. Raw data were converted to nanograms per gram of wet
tissue by comparison to a standard curve of synthetic A.
Stereologic analysis of basal forebrain cholinergic neurons. To visualize
basal forebrain cholinergic neurons (BFCNs), every fourth 50 m sec-
tion through the entire anterior–posterior axis of the basal forebrain was
stained. Systematic random sampling and unbiased stereology were used
via StereoInvestigator software to determine the number and volume of
BFCNs, according to methods similar to those previously established by
our laboratory (Yeo et al., 1997). Using the optical disector probe for
sampling, the region comprising the medial septum, and vertical and
horizontal limbs of the diagonal band was delineated under a 5 objec-
tive, and neurons were then counted under a 40 objective and cellular
volume of each neuron was estimated using the Nucleator probe. The
thickness of sections after histological processing was determined to be
19 –24 m; thus, disector height was set at 15 m to allow for 2 m
guard zones. The counting frame was set at 75 m  75 m and grid size
was set at 100 m  100 m. Using this sampling scheme, Gunderson
and Schaeffer coefficients of error were between 0.05 and 0.07.
Analysis of BFCN neurites. Neurites of basal forebrain cholinergic neu-
rons in the medial septal nucleus (MSN) and vertical limb of the diagonal
band of Broca (VDB), which project to hippocampal and cortical areas,
were analyzed using Neurolucida software (Microbrightfield) (Amendola
and Durand, 2008) to manually trace neurites proceeding from neuron
cell bodies in randomly selected fields comprising 50% of the total area.
One section per mouse, containing the MSN and VDB, between 1.2
and 0.8 mm relative to bregma was analyzed. Anatomical landmarks
contained within each section included the anterior part of the anterior
commissure and the major island of Calleja. Typically, only one section
from each series fit these criteria. Pictures (100; images shown in Fig. 6)
were taken with a Nikon Eclipse E600 microscope coupled with a
DXM1200F camera through multiple z-planes and in one to two adjacent
fields in the x and y axes. Photographs of z-planes within identical fields
were then manually merged and adjacent fields were manually tiled in
using Adobe Photoshop Version 9.02.
Analysis of cortical cholinergic terminals. In every 16th ChAT-stained
section between bregma 1.95 and 0.10, cholinergic fibers were visualized
using a Leica DM IRE2 light microscope. One 20 field covering the
majority of the cingulate cortex was analyzed for each section, for a total
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of three to seven sections per mouse. Percent-
age area occupied by cholinergic fibers was
determined using ImageProPlus threshold-
ing software (Media Cybernetics).
Statistical analyses. Statistical analyses of all
experiments used ANOVA followed by the
Student–Newman–Keuls post hoc test, except
the studies described in Figure 5, in which two-
tailed t tests were used. Significance was set at
p  0.05. For all figures, *p  0.05, **p  0.01,
and ***p  0.001.
Results
p75 NTR interacts with A oligomers
It has been reported that A(1-40) aggre-
gates bind to p75 NTR on cell surfaces;
however, the structure of these aggregates
was not determined (Yaar et al., 1997,
2002). We used FRET analysis to deter-
mine whether oligomers derived from
A(1-42) interact with the extracellular
domain of p75 NTR. FRET is an efficient
technique to study protein–protein inter-
actions, in which light excitation of a do-
nor molecule elicits energy transfer to an
acceptor when the two are in close prox-
imity (1–10 nm) (Vogel et al., 2006), and
has been used to study ligand–receptor in-
teractions (Whitby et al., 2006; Yamamoto
et al., 2008). A oligomers were generated
using a well established protocol (Stine et
al., 2003) that has been shown by several
laboratories to produce relatively pure oli-
gomeric preparations (Dahlgren et al., 2002;
Maloney et al., 2005). AFM imaging revealed that unlabeled A
(supplemental Fig. S2A,B, available at www.jneurosci.org as supple-
mental material) and fluorescein-labeled A (supplemental Fig.
S2C,D, available at www.jneurosci.org as supplemental material)
prepared by the HFIP protocol form oligomers as expected. Particle
analysis of unlabeled (supplemental Fig. S2B, available at www.
jneurosci.org as supplemental material) and fluorescein-labeled A
(supplemental Fig. S2D, available at www.jneurosci.org as supple-
mental material) demonstrated formation of oligomers in both
preparations. The resolution of the technique did not allow quanti-
tation of the size distributions of the oligomeric populations; there-
fore, the possibility that the labeling process affected oligomer struc-
ture cannot be ruled out. The finding that 99% of aggregates were
5 nm in z-height confirmed the absence of larger aggregate forms
such as fibrils which by AFM would have been readily detected (Yang
et al., 2008). Of note, the presence of A monomers in these prepa-
rations cannot be ruled out.
Emission intensities of fluorescein-A and fluorescein-NGF
in the presence and absence of Cy3B-p75 NTR are shown in Figure
1. Solutions containing Cy3B-p75 NTR with fluorescein-A or
fluorescein-NGF show decreased fluorescein fluorescence
around 520 nm, accompanied by increased Cy3B fluorescence at
570 nm relative to emission intensities of fluorescein-NGF and
fluorescein-A in the absence of p75 NTR. This pattern indicates
energy transfer occurring from fluorescein to Cy3B groups
within 10 nm, and that NGF and A oligomers interact with the
extracellular domain of p75 NTR. In positive control studies
(FITC-streptavidin/Cy3B-BtIgG), 20% FRET was detected,
whereas interactions of FITC-A and Cy3B-p75 NTR produced an
unusually large FRET signal (50%). This finding suggested at
least two possible explanations. First, multiple aggregates of
FITC-A could bind to one Cy3B-labeled p75 NTR and thereby
increase the probability that FRET occurs. Second, binding of
multiple FITC-A oligomers to p75 NTR could result in self-
quenching of FITC fluorescence and thereby increase the appar-
ent FRET signal, a well documented phenomenon (Lakowicz et
al., 2003). To determine the possible contribution of these mech-
anisms, fluorophores were reversed (FITC-p75 NTR and Cy3B-
A), resulting in a 20% energy transfer. This result is consistent
with self-quenching of FITC-labeled A oligomers, and indicates
that multiple A oligomers may bind to a single p75 NTR mole-
cule. In contrast, FRET did not occur when fluorescein-A was
incubated with heat-denatured Cy3B-p75 NTR, and no FRET was
observed when fluorescein-A was incubated solely with Cy3B-
BSA. Overall, these data support a specific interaction between
A and p75 NTR.
p75 NTR enables A-induced neuron death
To further characterize the functional consequences of p75 NTR
signaling in the context of A exposure, we tested the ability of
A oligomers to induce neuron death of neurons derived from
p75 NTR/ and p75 NTR/ mice, in which exon III, encoding the
majority of the extracellular domain, has been deleted, but which
express a truncated protein containing the transmembrane and
intracellular domains of p75 NTR. Previous studies in which A was
injected into the hippocampus of p75NTR/ and p75NTR/ mice
demonstrated protection from basal forebrain cholinergic
neuron loss in mice expressing mutant p75 (Sotthibundhu et
al., 2008). In addition, hippocampal neurons derived from
p75 NTR/ mice exhibited the absence of A-induced cell death
at 24 h in vitro. In the present studies we examined A effects in
Figure 1. A oligomers interact with the extracellular domain of p75 NTR. For FRET analysis, the indicated proteins linked to
either fluorescein or Cy3B were incubated at 500 nM in PBS solution containing 0.7% BSA. The intensity of fluorescent emissions
from 500 to 750 nm was measured after excitation at  490 nm ( y-axis  fluorescent activity in arbitrary units). Conditions in
which FRET occurred are indicated by bold lines. Incubation of fluorescein-labeled Streptavidin, NGF, and A alone demonstrated
no FRET. Incubation of fluorescein-labeled A with denatured p75 NTR-Cy3B or BSA-Cy3B also demonstrated no FRET. As a positive
control, fluorescein-labeled Streptavidin (SA-FITC) was reacted with Cy3B-labeled biotinylated IgG (IgG-Bt Cy3B), resulting in a
25% energy transfer as indicated by decreased fluorescein fluorescence at 520 nm, accompanied by increased Cy3B fluorescence at
570 nm (bold line). Incubation of fluorescein-NGF or fluorescein-A with Cy3B-p75 NTR exhibited FRET (24% energy transfer for
NGF-p75 and 50% for A-p75 NTR, both lines shown in bold) and, thereby, NGF and A interaction with p75 NTR. The relatively high
transfer energy (50%) in the A-p75 NTR condition raised the possibility of A-FITC self-quenching due to potential A self-
aggregation. To further assess A-p75 NTR interaction, a solution containing A-Cy3B and p75 NTR-FITC (fluorophore reversal) was
submitted to FRET analysis and demonstrated 20% energy transfer (data not shown), confirming a molecular interaction between
p75 NTR and A. Data are representative of three separate experiments.
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additional culture models. Since the degree of maturation of cul-
tured neurons can affect responses to A, we determined whether
the death-promoting activity of oligomeric A(1-42) in hip-
pocampal cultures allowed to mature for 5– 6 d is p75 NTR depen-
dent. In addition, we determined whether A toxicity is p75 NTR
dependent in cultures of basal forebrain cholinergic neurons.
Under each of these culture conditions, we determined that
95% of cells were p75 NTR-expressing neurons (supplemental
Fig. S1, available at www.jneurosci.org as supplemental mate-
rial). Previous work in our laboratory established that a 72 h
period is required to observe maximum A toxicity in neuronal
cultures (data not shown). After 72 h treatment with fresh culture
medium (CM) alone or CM containing increasing doses (1, 2.5,
5, and 10 M) of oligomeric A, hippocampal neuron survival
was quantified based on morphological criteria as described in
Materials and Methods. p75 NTR/ hippocampal neurons exhib-
ited dose-dependent increases in A-induced neuron death (Fig.
2A). A also induced death in p75 NTR/ hippocampal neurons
at most doses tested (2.5, 5, and 10 M). However, p75NTR/
cultures demonstrated a 1.5- to 2-fold rightward shift in the dose–
response curve, with 25– 40% increased survival at doses of 1,
2.5, and 5 M A. Maximum toxicity in
both p75NTR/ and p75NTR/ cultures
was reached at 10 M A. p75NTR/ and
p75NTR/ basal forebrain cultures re-
sponded with a similar shift in dose–re-
sponse curve and increased survival of
p75NTR/ cells (Fig. 2B).
To verify these findings, TUNEL anal-
ysis was performed in p75 NTR/ and
p75 NTR/ hippocampal cultures (Fig.
2C). In concordance with the morpho-
logic data, dose-dependent increases in
neuron death (% TUNEL/DAPI) were
observed in neurons of both genotypes. In
p75 NTR/ cultures, a rightward shift in
the dose–response curve was again ob-
served with a reduction in cell death by
20 – 40% compared with p75 NTR/ cul-
tures at intermediate doses. In cultures of
both genotypes, maximum toxicity was
reached at 10 M A. Together, these
findings show that hippocampal and basal
forebrain neuron cell death induced by
oligomeric A is only partially p75 NTR de-
pendent when observed after 72 h of A
exposure.
To confirm the modulatory role of
p75 NTR using a strategy distinct from ge-
netic knock-down, we tested the ability of
a well characterized p75 NTR-blocking an-
tibody, 9651, directed against the cysteine
repeat regions II, III, and IV of the extra-
cellular domain of p75 NTR, to decrease A
toxicity in hippocampal neurons (Fig.
2D). Neither anti-p75 NTR nor an IgG
control affected neuron survival relative
to baseline; however, anti-p75 NTR (but
not the IgG control) completely inhibited
death induced by 5 M A, a finding sim-
ilar to that of a previous study which used
a p75 NTR antibody directed to the extra-
cellular domain of p75 NTR (Sotthibundhu
et al., 2008). In contrast, at 10 M A, addition of anti-p75 NTR
was only partially protective, consistent with the finding of partial
protection in p75NTR/ cultures at higher doses of A. Thus,
our data support the view that p75 NTR significantly contributes
to or enables A-induced hippocampal neuronal death. How-
ever, a significant, though diminished, A toxicity persists in the
absence of normal p75 NTR signaling. The present study also dem-
onstrated a similar role for p75 NTR in cultured basal forebrain
cholinergic neurons, indicating a potential fundamental property
of p75 NTR in mediating or enabling A toxicity that is not con-
fined to hippocampal neurons.
p75 NTR enables A-induced neuritic dystrophy
Neuritic dystrophy, including abnormally tortuous and atrophic
neurites (Knowles et al., 1999; Tsai et al., 2004), is part of a spec-
trum of degenerative changes which results from cytoskeletal de-
rangement (Heredia et al., 2006), precedes neuron death (Grace
et al., 2002), and manifests early in AD (Braak et al., 2006). Unlike
cell death, the presence of neuritic dystrophy in early stages of AD
and its likely role in contributing to early stages of dementia make
it an important morphologic feature relevant to potential thera-
Figure 2. p75 NTR modulates A-induced neuron death. p75 NTR/ or p75 NTR/ neurons, 6 –7 DIV, were treated with
increasing doses of A for 72 h then fixed in fresh paraformaldehyde. A, B, Hippocampal (A) or basal forebrain (B) neurons were
photographed under phase contrast microscopy and survival was quantified based on morphological criteria. p75 NTR/ and
p75 NTR/ neurons each exhibited dose-dependent decreases in survival. In both hippocampal and basal forebrain cultures,
p75 NTR/ neurons showed significantly less A-induced death than p75 NTR/ neurons at multiple A doses, with 25– 40%
more neurons surviving (indicated by asterisks; see Materials and Methods for explanation). Hippocampal neuron data represent
n  46 –56 fields from six separate cultures (p75 NTR/) or 30 – 40 fields from four separate cultures (p75 NTR/). Basal
forebrain neuron data represent n  28 –38 fields from four separate p75 NTR/ and p75 NTR/ cultures. C, To confirm the
morphologic findings described in A, B, hippocampal neuron death was quantified by TUNEL analysis. p75 NTR/ and
p75 NTR/ hippocampal neurons each exhibited increases in death proportional to the dose of A; however, at multiple doses of
A, p75 NTR/ neurons exhibited only 60 – 80% of death exhibited by p75 NTR/. Data represent n  80 –160 fields from
seven separate cultures (p75 NTR/) or 70 – 89 fields from six separate cultures (p75 NTR/). D, To confirm the modulatory
effect of p75 NTR on A-induced neuron death using an independent method, 6 –7 DIV p75 NTR/ or p75 NTR/ hippocampal
neurons were treated with fresh CM alone, or in the presence or absence of A, p75 NTR antibody, or control IgG. p75 NTR antibody
(but not IgG control) prevented entirely A-induced neuron death when treated with 5 M A, whereas the protective effect was
significantly diminished when neurons were treated with 10 M A. Data represent the means of n  20 –30 fields from six
independent experiments.
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peutic targeting. The role of p75 NTR in
mediating A-induced neuritic dystro-
phy has not been previously explored. In
hippocampal cultures allowed to mature
in vitro for 21 d, a period during which
mature forms of tau protein become ex-
pressed, we and others (Ferreira et al.,
1997; Yang et al., 2008) have observed that
48 h treatment with oligomeric A results
in minimal cell death. Instead, and per-
haps more relevant to early and mid stages
of AD, we found excessive tortuosity and
diminished neurite volume resembling
dystrophic features found in AD.
The 21 DIV p75NTR/ and p75NTR/
hippocampal neurons were treated with 5
M A for 48 h, then fixed and stained for
MAP-2 to visualize neurites by fluores-
cence microscopy (Fig. 3). In the presence
of CM alone, p75 NTR/ and p75 NTR/
neurites exhibited relatively straight
courses with little tortuosity (Fig. 3, A and
C, respectively). Treatment with 5 M A
resulted in pronounced dystrophic
changes including loss of normal straight
appearance in p75 NTR/ neurites (Fig.
3B), whereas the appearance of dystro-
phy was mild to absent in p75 NTR/ cul-
tures (Fig. 3D). Neuritic dystrophy was
then quantified to generate MDC scores,
indicative of neurite tortuosity (Fig. 3E).
Treatment with A induced a signifi-
cant increase in MDC in p75 NTR/ cul-
tures, whereas this effect was entirely
absent in p75 NTR/ cultures. To further
investigate degenerative A-induced
changes, we measured neurite volume and
found that A treatment resulted in signifi-
cantly diminished neurite volume in
p75 NTR/ cultures, an effect that was not
observed in p75 NTR/ cultures (Fig. 3F).
These results indicate that full-length
p75 NTR signaling is required for A-induced neuritic dystrophy.
p75 NTR mediates A-induced c-Jun activation
The c-Jun transcription factor is downstream of c-Jun kinase, a
pathway which has been previously linked to p75 NTR and which
is critical in A-induced neurodegeneration (Bozyczko-Coyne et
al., 2001; Morishima et al., 2001; Fogarty et al., 2003). A-
induced c-Jun activation has not been investigated in p75 NTR/
neurons. To do so, 6 –7 DIV p75 NTR/ and p75 NTR/ cultures
were treated with 5 M A for 10 –12 h, then fixed and stained for
phosphorylated c-Jun and DAPI. Quantitation of phosphory-
lated c-Jun has been established as an indicator of c-jun activa-
tion (Smith and Deshmukh, 2007; Thakur et al., 2007; Yang et al.,
2008). Fluorescence microscopy revealed that relative to culture
medium alone (Fig. 4A), a larger number of p75 NTR/ neurons
treated with A exhibited p-c-Jun-positive nuclei (Fig. 4B). In
contrast, this effect appeared to be absent in p75 NTR/ cultures
treated with CM or A (Fig. 4, C and D, respectively). As shown
in Figure 4E, quantitation revealed that in p75 NTR/ cultures,
A induced an 2.5-fold increase in the percentage of p-c-Jun-
positive nuclei, whereas A-induced c-Jun activation was lost
entirely in p75 NTR/ cultures.
Generation of a transgenic mouse model of AD lacking
wild-type p75 NTR
Although a role for p75 NTR in contributing to A-mediated tox-
icity has been demonstrated in vitro, its role in a chronic in vivo
AD model is unknown. To address this question, p75 NTR exon
III/ mice were crossed with Thy1-hAPP Lond/Swe transgenic
mice, which exhibit chronic excessive levels of A in brain tissue,
plaque formation, and neuritic dystrophy (Rockenstein et al.,
2001). Thy1-hAPP Lond/Swe mice possessing or lacking the
transgene are referred to as APP Lond/Swe and APP wt, respectively.
Supplemental Table S1, available at www.jneurosci.org as supple-
mental material, summarizes mice used in this study, including
the frequency with which each of the six possible genotypes was
observed compared with the expected frequency. Exon III
p75 NTR/ mice were present at weaning at 50% of the ex-
pected rate, regardless of whether they possessed the APP Lond/Swe
transgene. APP Lond/Swe mice were noted to exhibit 70% survival
within the first 4 months of age. We have routinely observed both
of these effects in each of our p75 NTR and Thy1-hAPP Lond/Swe
Figure 3. p75 NTR mediates A-induced neuritic dystrophy. A–D, p75 NTR/ or p75 NTR/ hippocampal neurons, 21 DIV,
were treated with fresh CM alone or with CM containing 5 M A for 48 h, then fixed in fresh paraformaldehyde and stained for
MAP-2. Neurons were photographed with fluorescence microscopy. In the presence of CM alone, p75 NTR/ (A) and p75 NTR/
(C) neurites were indistinguishable and without excessive tortuosity. In the presence of A, p75 NTR/ neurons exhibited
pronounced neuritic dystrophy and shrinkage (B), whereas the appearance of dystrophy in p75 NTR / neurons was greatly
diminished (D). E, Quantitation of neurite tortuosity revealed a significant 1.3-fold increase in mean differential curvature in
p75 NTR/ neurons treated with A, whereas this effect was absent in p75 NTR/ neurons. Data represent the means from n 
25–31 fields from three separate p75 NTR/ cultures and four p75 NTR/ cultures. F, Quantitation of neurite volume normalized
to neurite length demonstrated that treatment of p75 NTR/ neurons with A resulted in a 42% decrease in neurite volume,
whereas this effect was absent in p75 NTR/ cultures. Data represent the means from 12 to 14 fields from three separate cultures
for each genotype.
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transgenic mouse colonies. APP Lond/Swe mice expressing only
mutant p75 NTR (APP Lond/Swe, p75 NTR/) were present at wean-
ing at 6% of the time (relative to the predicted 12.5%) and
exhibited 60% survival before 4 months of age. Thus, it appears
that decreased survival in these mice was no more than expected
from the separate effects of mutant p75 NTR and the APP trans-
gene. APP Lond/Swe, p75 NTR/ mice exhibited no gross abnor-
malities and were allowed to age until 5.5–7.5 months, a time at
which plaques and associated neurodegeneration are present in
multiple brain areas including cortex and hippocampus in
APPLond/Swe mice (Rockenstein et al., 2001).
Hippocampal neuritic dystrophy but not amyloid levels are
diminished in APP Lond/Swe, p75 NTR/ mice
To determine whether p75 NTR plays a role in chronic accumula-
tion and deposition of A, sections from APP Lond/Swe,
p75 NTR/ or p75 NTR/ mice were colabeled with thioflavin-S
and anti-APP 8E5 antibody to identify amyloid deposits and neu-
ritic dystrophy, respectively. As described in Materials and Meth-
ods, 8E5 does not label A in plaques, but is an established
marker of dystrophic neurites (Cras et al., 1991; Games et al.,
1995; Schenk et al., 1999). As shown in Figure 5, in APP Lond/Swe,
p75 NTR/ mice, dystrophic neurites (upper left) and associ-
ated plaques (upper right) were prominent. Costaining with
thioflavin-S revealed that many but not all dystrophic neurites
were associated with amyloid deposits (data not shown). In
APP Lond/Swe, p75 NTR/ mice, neuritic dystrophy appeared di-
minished (Fig. 5, lower left), whereas plaques did not appear to be
affected (lower right). Plaque area quantification in APP Lond/Swe,
p75 NTR/ and p75 NTR/ mice revealed no significant differ-
ences in hippocampal or cortical plaque load (data not shown).
APP wt mice, which exhibit a complete absence of visible amyloid
deposits or neuritic dystrophy, were not included in the analysis.
These morphological plaque findings were consistent with ELISA
analysis, which revealed no significant differences in hippocam-
pal or cortical levels of soluble A(1-42). APP Lond/Swe,
p75 NTR/ mice contained, in the hippocampus, 9.5 
 0.5 ng of
A(1-42)/g of wet tissue and in the cortex, 13.4 
 1.3 ng/g. AP-
P Lond/Swe, p75 NTR/ mice contained, in the hippocampus, 9.2 

0.5 ng/g and in the cortex, 12.28 
 1.2 ng/g.
To quantitatively determine whether p75 NTR modulates AD-
like amyloid-induced neurodegeneration in vivo, hippocampal
neuritic dystrophy, as detected by 8E5 anti-APP antibody, was mea-
sured in the stratum lacunosum-moleculare, molecular layer of the
dentate gyrus, and stratum radiatum regions in APPLond/Swe,
p75 NTR/ and APP Lond/Swe, p75 NTR/ mice. This region con-
tains projection fibers of hippocampal pyramidal neurons and
granule cells, as well as septal cholinergic and entorhinal cortical
efferent fibers. The absence of APP-containing cell bodies, which
are also labeled by 8E5 antibody, within these layers facilitates
quantitation of dystrophic neurites. Many but not all of these
fibers are expected to express p75 NTR. Extensive 8E5 labeling of
cell bodies in cortical tissue prevented accurate quantitation of
neuritic dystrophy in the cortex. In APP Lond/Swe, p75 NTR/
mice, neuritic dystrophy (as quantitated by percentage of hip-
pocampal area immunostained by anti-APP 8E5) was decreased
to 34.5 
 11.1% (mean 
 SEM, p  0.01, n  6 APP Lond/Swe,
p75 NTR/ mice and 5 APP Lond/Swe, p75 NTR/ mice) of that
seen in APP Lond/Swe, p75 NTR/ mice. The finding of reduced
hippocampal neuritic dystrophy in the setting of unchanged A
levels mirrors the in vitro observation that at a given dose of A,
neuritic dystrophy is reduced in p75 NTR/ cultures, and pro-
vides the first evidence that p75 NTR signaling plays a major role in
the development of AD-like pathology in a chronic in vivo model
of AD. Since APP staining is not specific for p75 NTR-expressing
neurites, we may have underestimated the effect of removing
p75 NTR in this analysis.
Figure 4. p75 NTR mediates A-induced c-Jun activation. A–D, p75 NTR/ or p75 NTR/
hippocampal neurons, 6 –7 DIV, were treated with CM or CM containing 5 M A for 10 –12 h,
then fixed in fresh paraformaldehyde and immunostained for phospho-c-Jun and DAPI. Rela-
tive to CM alone (A), A-treatment of p75 NTR/ cells resulted in a higher frequency of p-c-
Jun-positive nuclei (B). In contrast, cultures of p75 NTR/ neurons treated with CM (C) or A
(D) appeared similar. E, Quantitative analysis revealed that A induced a significant 2.5-fold
increase in p-c-Jun-positive nuclei of p75 NTR/ neurons, whereas this effect was entirely
absent in p75 NTR/ neurons. Data represent the mean of n  40 –50 fields per experimental
condition from three independent experiments. A total of 300 – 600 neurons were analyzed per
condition; in the presence of CM alone, 5–10% of both p75 NTR/ and p75 NTR/ neurons
exhibited p-c-jun-positive nuclei.
Figure 5. Neuritic dystrophy but not amyloid deposition in Thy1-hAPP Lond/Swe mice is me-
diated by p75 NTR. Dystrophic neurites were visualized with anti-APP 8E5 antibody staining in
APP Lond/Swe, p75 NTR/ and p75 NTR/ mice. Upper left, APP Lond/Swe, p75 NTR/ mice
exhibit prominent neuritic dystrophy. Upper right, Costaining of the identical area with
thioflavin-S shows localization of dystrophic neurites with amyloid plaque. Lower left, Neuritic
dystrophy appears diminished in p75 NTR/ mice. Lower right, Costaining with thioflavin-S
demonstrates no gross change in plaque number or size in p75 NTR/ mice. Images were
acquired at 63. Scale bars, 25 m. Quantitation of amyloid load by hippocampal and cortical
plaque area measurement and ELISA quantitation of soluble A(1-42) concentration in hip-
pocampal and cortical extracts from APP Lond/Swe, p75 NTR/ and p75 NTR/ mice revealed
no differences (see Results for ELISA data).
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p75 NTR mediates amyloid-induced
BFCN neuritic dystrophy in
APP Lond/Swe mice
BFCNs comprise a population of neurons
in the brain which projects to cortical and
hippocampal targets, is critical for atten-
tion and cognition, and is particularly
vulnerable in aging and AD (Davies and
Maloney, 1976; Whitehouse et al., 1982).
p75 NTR is known to regulate the size and
projection fibers of BFCNs (Yeo et al.,
1997; Greferath et al., 2000). To deter-
mine whether p75 NTR contributes to
AD-like atrophy or loss of BFCNs in
Thy1-hAPP Lond/Swe mice, we performed
unbiased stereological analysis to assess
the number and cell body volume of
BFCNs from APP wt and APP Lond/Swe mice
each containing either wild-type or mu-
tant p75 NTR. Consistent with previous
work by our group and others, there was a
trend toward increased number of BFCNs
in mice lacking normal p75 NTR, and
BFCN volume was significantly increased
in APP wt and APP Lond/Swe p75 NTR/
mice. However, APP Lond/Swe mice do not
exhibit decreased BFCN absolute number
or volume relative to APP wt (supplemen-
tal Table S2, available at www.jneurosci.
org as supplemental material). Thus,
shrinkage or frank loss of BFCN cell bod-
ies may represent end-stage degeneration
not detectable in APP Lond/Swe mice be-
tween 5.5 and 7.5 months of age.
To determine whether earlier stage
changes such as BFCN neuritic dystrophy
are evident in APP Lond/Swe mice, we assessed the structure of
neurite trees proceeding from BFCNs of APP wt and APP Lond/Swe
mice in the presence or absence of wild-type p75 NTR. Represen-
tative images of BFCN neurites are shown in Figure 6. Relative to
APP wt, p75 NTR/ and APP wt, p75 NTR/ mice (Fig. 6A,B),
BFCN ChAT-positive neurites in APP Lond/Swe mice expressing
wild-type p75 NTR (Fig. 6C) appeared shorter and thinner. These
changes were not observed in APP Lond/Swe, p75 NTR/ mice (Fig.
6D). Quantitative analysis demonstrated that relative to APP wt
mice, APP Lond/Swe mice expressing wild-type p75 NTR exhibited
significantly decreased average neurite length (15%) and vol-
ume (30%). In BFCN trees of APP Lond/Swe mice expressing
mutant p75 NTR, these degenerative changes were entirely ab-
sent, with neurite morphology resembling that of APP wt mice
(Fig. 6 E, F ).
To establish whether cholinergic neurite changes observed
in the basal forebrain result in loss of projections in areas of
target innervation, density of ChAT-positive fibers in the cin-
gulate cortex was quantified. Figure 7, A to D, shows that
relative to APP wt mice, cholinergic fibers in the cingulate cor-
tex in APP Lond/Swe, p75 NTR/ mice appeared diminished in
density, whereas this was not observed in APP Lond/Swe,
p75 NTR/ mice. Quantitation revealed an 50% decrease in
cholinergic projections in the cortex of APP Lond/Swe,
p75 NTR/ mice relative to APP wt mice. This decrease was
mitigated entirely in APP Lond/Swe, p75 NTR/ mice (Fig. 7E).
In fact, relative to APP wt, p75 NTR / mice, APP Lond/Swe,
p75 NTR/ mice had substantially more dense cholinergic
fibers ( p  0.05). This suggests that interference with p75 NTR
signaling prevents degeneration of basal forebrain cholinergic
projections in an in vivo model of chronic A-induced
degeneration.
Discussion
These studies demonstrate that oligomeric A(1-42) associ-
ates with the extracellular domain of p75 NTR, that the ability of
oligomeric A to induce neurite degeneration (in addition to
neuronal death) requires the presence of intact, wild-type
p75 NTR, and that p75 NTR exon III deletion significantly re-
duces neuritic dystrophy and loss of BFCN neurites in a
chronic, transgenic model of A overexpression. The findings
that A-induced toxicity is reduced in hippocampal and basal
forebrain neuronal cultures lacking p75NTR are consistent with the
studies of Sotthibundhu et al. (2008). However, the present
study further demonstrates that at a later time point, in more
mature cultures, A-induced death is not entirely prevented
in p75 NTR/ neurons.
Yaar et al. (1997, 2002) found that A(1-40) aggregates
bind to p75 NTR, suggesting a potential role for p75 NTR in me-
diating A effects. To determine whether oligomeric forms of
A(1-42) interact with p75 NTR, we performed FRET analysis
using fluorescein-labeled A(1-42), which forms oligomers
documented by AFM imaging. Energy transfer occurring be-
tween fluorophores linked to A oligomers and p75 NTR extra-
Figure 6. BFCN neuritic dystrophy in Thy1-hAPP Lond/Swe mice is mediated by p75 NTR. A–D, Representative 100
images of ChAT-stained neurites projecting from basal forebrain cholinergic neurons from APP wt, p75 NTR/ (A), APP wt,
p75 NTR/ (B), APP Lond/Swe, p75 NTR/ (C), and APP Lond/Swe, p75 NTR/ (D) mice are shown. Scale bar, 30 m. Many
neurites from APP Lond/Swe, p75 NTR/ mice exhibited degenerative changes, including interrupted segments, decreased
length, and decreased volume, whereas these effects were not apparent in APP Lond/Swe, p75 NTR/ mice. E, F, Neurite
trees projecting from BFCNs were manually traced using Neurolucida software. Relative to APP wt, p75 NTR/ mice, BFCN
neurites of APP Lond/Swe mice expressing wild-type p75 NTR exhibited decreased length (E) and volume (F ). However, in
APP Lond/Swe mice expressing p75 NTR/, these changes were entirely absent. Asterisks (see Materials and Methods for
explanation) represent statistically significant comparisons relative to APP Lond/Swe, p75 NTR/ mice. Data represent the
mean 
 SEM from n  6 APP wt, p75 NTR/ mice, 4 APP wt, p75 NTR/ mice, 7 APP Lond/Swe, p75 NTR/ mice, and 5
APP Lond/Swe, p75 NTR/ mice.
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cellular domain indicated a molecular interaction between A
and p75 NTR, consistent with the possibility that A oligomers
are ligands for p75 NTR. However, under these experimental
conditions, it is possible that monomeric forms of A also
interact with p75 NTR. Future work will further characterize
the forms of A binding to p75 NTR.
We found that removing p75 NTR exon III significantly
shifts A oligomer toxicity dose–response curves in hip-
pocampal and basal forebrain neurons, but p75 NTR does not
play an “all-or-none” role in mediating A-induced neuron
death as suggested by previous studies (Rabizadeh et al., 1994;
Yaar et al., 1997, 2002; Kuner et al., 1998; Perini et al., 2002;
Coulson, 2006; Sotthibundhu et al., 2008). Our findings are
also consistent with previous studies indicating that A likely
induces degeneration through multiple mechanisms and tar-
gets; these might include p75 NTR coreceptors such as LINGO
or Nogo (Barker, 2004) or other non-p75 targets such as inte-
grins or NMDA receptors (Dineley et al., 2001; Kayed et al.,
2004; Verdier and Penke, 2004). A oligomers could promote
degeneration through p75 NTR by a number of potential mech-
anisms. A-induced promotion of extracellular cleavage and
inhibition of -secretase cleavage of the p75 NTR C-terminal
domain has been reported, and may represent mechanisms by
which A signals through p75 NTR (Sotthibundhu et al., 2008).
However, p75 NTR signaling might also contribute to A-
induced neurodegeneration independently of a physical inter-
action with A.
Neuronal cytoskeletal perturbation, which is known to occur
earlier in AD than cellular death, may impact function and be
reversible (Grace et al., 2002; Lombardo et al., 2003; Brendza et
al., 2005). In contrast to p75 NTR/ matured hippocampal neu-
rons treated with A, the appearance of excessive tortuosity and
decreased volume was almost entirely absent in A-treated
p75 NTR/ neurons.
The findings that p75 NTR mediates or enables A-induced
neuron death and neuritic dystrophy in neuronal cultures led to
the question of whether p75 NTR plays any role in chronic, AD-
like degeneration in vivo. Relative to APP Lond/Swe, p75 NTR/
mice, APP Lond/Swe mice lacking full-length p75 NTR demonstrated
no change in brain amyloid or A concentration, but a 65%
decrease in hippocampal neuritic dystrophy was observed, indi-
cating that p75 NTR plays a substantial role in A-associated neu-
rodegeneration in vivo, a correlate of our observations in matured
hippocampal cultures.
p75 NTR is expressed by and regulates the trophic state of
BFCNs (Yeo et al., 1997; Greferath et al., 2000), and BFCN
degeneration has long been thought to play a major role in
diminished cognitive function associated with AD and aging
(Coyle et al., 1983; Salehi et al., 2003; Capsoni and Cattaneo,
2006). Direct, intraparenchymal infusion of synthetic A into
the hippocampus induces loss of basal forebrain cholinergic
neurons in p75NTR/ but not p75NTR/ mice (Sotthibundhu et
al., 2008), consistent with our in vitro findings in p75 NTR/
cultures. These observations raise the possibility that mutant
p75 NTR might also protect against BFCN degeneration in a
transgenic mouse model of AD. In Thy1-hAPP Lond/Swe mice,
as demonstrated here, and in most other transgenic AD mod-
els (McGowan et al., 2006), no significant loss of BFCNs
occurs. In contrast, neuritic degeneration, including that as-
sociated with BFCNs, has been documented in mouse models
of AD (Stokin et al., 2005) and in AD patients (Wong et al.,
1999; German et al., 2003; Stokin et al., 2005). In APP Lond/Swe,
p75 NTR/ mice, neurite trees of BFCNs exhibited decreased
length and volume, an effect that was entirely prevented in
APP Lond/Swe mice lacking wild-type p75 NTR. Furthermore,
cholinergic cortical fiber density was reduced by 50% in
APP Lond/Swe, p75 NTR/ mice but not in those lacking wild-
type p75 NTR. Thus, wild-type p75 NTR is necessary for
amyloid-associated BFCN neuritic dystrophy. One possible
explanation for this result is a developmental difference in
p75 NTR/ mice. However, there were no significant differ-
ences detected in the length or volume of BFCN neurite trees
in APP wt p75 NTR/ and p75 NTR/ mice, making this a less
likely possibility. Future studies to assess p75 NTR/ and
p75 NTR/, APP Lond/Swe mice in end stages of pathology,
and/or studies in which p75 NTR could be functionally re-
moved in later stages of degenerative change, might shed ad-
ditional light on the role of this receptor in amyloid-associated
BFCN degeneration.
Given the known range of A targets and mechanisms,
future treatment of AD will likely require the simultaneous
application of multiple distinct strategies to decrease A brain
levels and counteract its deleterious effects (Longo and Massa,
2004a; Longo et al., 2007). This work demonstrates a signifi-
cant contributory role of p75 NTR in A-induced degeneration,
and implicates p75 NTR as a major target in neuroprotective
strategies for AD.
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Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase
mediates amyloid -induced degeneration: a potential mechanism of
neuronal dystrophy in Alzheimer’s disease. J Neurosci 26:6533– 6542.
Hu XY, Zhang HY, Qin S, Xu H, Swaab DF, Zhou JN (2002) Increased
p75(NTR) expression in hippocampal neurons containing hyperphos-
phorylated tau in Alzheimer patients. Exp Neurol 178:104 –111.
Huber LJ, Chao MV (1995) Mesenchymal and neuronal cell expression of
the p75 neurotrophin receptor gene occur by different mechanisms. Dev
Biol 167:227–238.
Jana A, Pahan K (2004) Fibrillar amyloid-beta peptides kill human primary
neurons via NADPH oxidase-mediated activation of neutral sphingomyeli-
nase. Implications for Alzheimer’s disease. J Biol Chem 279:51451–51459.
Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG
(2004) Permeabilization of lipid bilayers is a common conformation-
dependent activity of soluble amyloid oligomers in protein misfolding
diseases. J Biol Chem 279:46363– 46366.
Khan AA, Mao XO, Banwait S, Jin K, Greenberg DA (2007) Neuroglobin
attenuates beta-amyloid neurotoxicity in vitro and transgenic Alzheimer
phenotype in vivo. Proc Natl Acad Sci U S A 104:19114 –19119.
Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, Stanley
HE, Hyman BT (1999) Plaque-induced neurite abnormalities: implica-
tions for disruption of neural networks in Alzheimer’s disease. Proc Natl
Acad Sci U S A 96:5274 –5279.
Kuner P, Schubenel R, Hertel C (1998) Beta-amyloid binds to p57NTR and
activates NFkappaB in human neuroblastoma cells. J Neurosci Res
54:798 – 804.
Lakowicz JR, Malicka J, D’Auria S, Gryczynski I (2003) Release of the self-
quenching of fluorescence near silver metallic surfaces. Anal Biochem
320:13–20.
Lee KF, Li E, Huber LJ, Landis SC, Sharpe AH, Chao MV, Jaenisch R (1992)
Targeted mutation of the gene encoding the low affinity NGF receptor
p75 leads to deficits in the peripheral sensory nervous system. Cell
69:737–749.
Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ,
Hyman BT (2003) Amyloid- antibody treatment leads to rapid nor-
malization of plaque-induced neuritic alterations. J Neurosci
23:10879 –10883.
Longo FM, Massa SM (2004a) Neuroprotective strategies in Alzheimer’s
disease. NeuroRx 1:117–127.
Longo FM, Massa SM (2004b) Neurotrophin-based strategies for neuro-
protection. J Alzheimers Dis 6:S13–17.
Longo FM, Massa SM (2008) Small molecule modulation of p75 neurotro-
phin receptor functions. CNS Neurol Disord Drug Targets 7:63–70.
Longo FM, Yang T, Knowles JK, Xie Y, Moore LA, Massa SM (2007) Small
molecule neurotrophin receptor ligands: novel strategies for targeting
Alzheimer’s disease mechanisms. Curr Alzheimer Res 4:503–506.
Maloney MT, Minamide LS, Kinley AW, Boyle JA, Bamburg JR (2005)
-Secretase-cleaved amyloid precursor protein accumulates at actin inclu-
sions induced in neurons by stress or amyloid beta: a feedforward mechanism
for Alzheimer’s disease. J Neurosci 25:11313–11321.
McGowan E, Eriksen J, Hutton M (2006) A decade of modeling Alzheimer’s
disease in transgenic mice. Trends Genet 22:281–289.
Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N, Perrin S,
Sands B, Crowell T, Cate RL, McCoy JM, Pepinsky RB (2004) LINGO-1 is
a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci
7:221–228.
Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ,
Shirasaki Y, Greenberg ME (2001) -Amyloid induces neuronal apo-
ptosis via a mechanism that involves the c-Jun N-terminal kinase pathway
and the induction of Fas ligand. J Neurosci 21:7551–7560.
Mufson EJ, Kordower JH (1992) Cortical neurons express nerve growth
factor receptors in advanced age and Alzheimer disease. Proc Natl Acad
Sci U S A 89:569 –573.
Noda-Saita K, Terai K, Iwai A, Tsukamoto M, Shitaka Y, Kawabata S, Okada
M, Yamaguchi T (2004) Exclusive association and simultaneous ap-
pearance of congophilic plaques and AT8-positive dystrophic neurites in
Tg2576 mice suggest a mechanism of senile plaque formation and pro-
gression of neuritic dystrophy in Alzheimer’s disease. Acta Neuropathol
108:435– 442.
Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C,
Kliemannel M, Schwarz E, Willnow TE, Hempstead BL, Petersen CM
(2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature
427:843–848.
Perini G, Della-Bianca V, Politi V, Della Valle G, Dal-Pra I, Rossi F, Armato U
(2002) Role of p75 neurotrophin receptor in the neurotoxicity by beta-
amyloid peptides and synergistic effect of inflammatory cytokines. J Exp
Med 195:907–918.
Rabizadeh S, Bitler CM, Butcher LL, Bredesen DE (1994) Expression of the
10636 • J. Neurosci., August 26, 2009 • 29(34):10627–10637 Knowles et al. • p75NTR Promotes A-Induced Neuritic Dystrophy
low-affinity nerve growth factor receptor enhances beta-amyloid peptide
toxicity. Proc Natl Acad Sci U S A 91:10703–10706.
Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E (2001) Early formation
of mature amyloid-beta protein deposits in a mutant APP transgenic model
depends on levels of Abeta(1-42). J Neurosci Res 66:573–582.
Salehi A, Delcroix JD, Mobley WC (2003) Traffic at the intersection of neu-
rotrophic factor signaling and neurodegeneration. Trends Neurosci
26:73– 80.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang
J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I,
Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker
S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization
with amyloid-beta attenuates Alzheimer-disease-like pathology in the
PDAPP mouse. Nature 400:173–177.
Smith MI, Deshmukh M (2007) Endoplasmic reticulum stress-induced ap-
optosis requires bax for commitment and Apaf-1 for execution in primary
neurons. Cell Death Differ 14:1011–1019.
Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangnipon W, Coulson
EJ (2008) -Amyloid1-42 induces neuronal death through the p75 neu-
rotrophin receptor. J Neurosci 28:3941–3946.
Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ (2003) In vitro character-
ization of conditions for amyloid-beta peptide oligomerization and fibril-
logenesis. J Biol Chem 278:11612–11622.
Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman
R, Davies P, Masliah E, Williams DS, Goldstein LS (2005) Axonopathy
and transport deficits early in the pathogenesis of Alzheimer’s disease.
Science 307:1282–1288.
Susen K, Blöchl A (2005) Low concentrations of aggregated beta-amyloid
induce neurite formation via the neurotrophin receptor p75. J Mol Med
83:720 –735.
Thakur A, Wang X, Siedlak SL, Perry G, Smith MA, Zhu X (2007) c-Jun
phosphorylation in Alzheimer disease. J Neurosci Res 85:1668 –1673.
Tsai J, Grutzendler J, Duff K, Gan WB (2004) Fibrillar amyloid deposition
leads to local synaptic abnormalities and breakage of neuronal branches.
Nat Neurosci 7:1181–1183.
Verdier Y, Penke B (2004) Binding sites of amyloid beta-peptide in cell
plasma membrane and implications for Alzheimer’s disease. Curr Protein
Pept Sci 5:19 –31.
Vogel SS, Thaler C, Koushik SV (2006) Fanciful FRET. Sci STKE 2006:re2.
Wang KC, Kim JA, Sivasankaran R, Segal R, He Z (2002) P75 interacts with
the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature
420:74 –78.
Whitby RJ, Dixon S, Maloney PR, Delerive P, Goodwin BJ, Parks DJ, Willson
TM (2006) Identification of small molecule agonists of the orphan nu-
clear receptors liver receptor homolog-1 and steroidogenic factor-1.
J Med Chem 49:6652– 6655.
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982)
Alzheimer’s disease and senile dementia: loss of neurons in the basal
forebrain. Science 215:1237–1239.
Wong TP, Debeir T, Duff K, Cuello AC (1999) Reorganization of cholin-
ergic terminals in the cerebral cortex and hippocampus in transgenic mice
carrying mutated presenilin-1 and amyloid precursor protein transgenes.
J Neurosci 19:2706 –2716.
Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest BA
(1997) Binding of beta-amyloid to the p75 neurotrophin receptor in-
duces apoptosis. A possible mechanism for Alzheimer’s disease. J Clin
Invest 100:2333–2340.
Yaar M, Zhai S, Fine RE, Eisenhauer PB, Arble BL, Stewart KB, Gilchrest BA
(2002) Amyloid beta binds trimers as well as monomers of the 75-kDa
neurotrophin receptor and activates receptor signaling. J Biol Chem
277:7720 –7725.
Yaar M, Zhai S, Panova I, Fine RE, Eisenhauer PB, Blusztajn JK, Lopez-
Coviella I, Gilchrest BA (2007) A cyclic peptide that binds p75(NTR)
protects neurones from beta amyloid (1-40)-induced cell death. Neuro-
pathol Appl Neurobiol 33:533–543.
Yamamoto T, Chen HC, Guigard E, Kay CM, Ryan RO (2008) Molecular
studies of pH-dependent ligand interactions with the low-density li-
poprotein receptor. Biochemistry 47:11647–11652.
Yang T, Knowles JK, Lu Q, Zhang H, Arancio O, Moore LA, Chang T, Wang
Q, Andreasson K, Rajadas J, Fuller GG, Xie Y, Massa SM, Longo FM
(2008) Small molecule, non-peptide p75 ligands inhibit A-induced
neurodegeneration and synaptic impairment. PLoS ONE 3:e3604.
Yeo TT, Chua-Couzens J, Butcher LL, Bredesen DE, Cooper JD, Valletta JS,
Mobley WC, Longo FM (1997) Absence of p75NTR causes increased
basal forebrain cholinergic neuron size, choline acetyltransferase activity,
and target innervation. J Neurosci 17:7594 –7605.
Knowles et al. • p75NTR Promotes A-Induced Neuritic Dystrophy J. Neurosci., August 26, 2009 • 29(34):10627–10637 • 10637
